JAMES A SHAYMAN, MD
Osteopathic Medicine at Medical Center Dr, Ann Arbor, MI
License number
Michigan 4301050556
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Michigan 4301050556
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
1500 EAST Medical Center Dr, Ann Arbor, MI 48109
Phone
(734) 888-2871
(734) 936-2047
(734) 936-2047
Personal information
See more information about JAMES A SHAYMAN at radaris.comName
Address
Phone
1890 Snowberry Ridge Rd, Ann Arbor, MI 48103
322 Mulholland St, Ann Arbor, MI 48103
Ann Arbor, MI
1890 Snowberry Ridge Rd, Scio Township, MI 48103
322 Mulholland St, Ann Arbor, MI 48103
Organization information
See more information about JAMES A SHAYMAN at bizstanding.comJames Shayman MD
1500 E Medical Ctr Dr, Ann Arbor, MI 48109
Industry:
Internist
Phone:
(734) 936-4890 (Phone)
James Alan Shayman
Professional information
See more information about JAMES A SHAYMAN at trustoria.com
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
US Patent:
2012012, May 17, 2012
Filed:
Oct 13, 2011
Appl. No.:
13/272949
Inventors:
James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 38/46, A61P 29/00
US Classification:
424 946
Abstract:
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
US Patent:
8052970, Nov 8, 2011
Filed:
Jun 30, 2009
Appl. No.:
12/495209
Inventors:
James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 38/46
US Classification:
424 946, 424 94, 435375, 435 19
Abstract:
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
Glucosylceramide Synthase Inhibitors And Therapeutic Methods Using The Same
Glucosylceramide Synthase Inhibitors And Therapeutic Methods Using The Same
US Patent:
2013009, Apr 18, 2013
Filed:
Oct 15, 2012
Appl. No.:
13/652016
Inventors:
The Regents of The University of Michigan - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Liming Shu - Ann Arbor MI, US
Michael William Wilson - Ann Arbor MI, US
Richard F. Keep - Ann Arbor MI, US
James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Liming Shu - Ann Arbor MI, US
Michael William Wilson - Ann Arbor MI, US
Richard F. Keep - Ann Arbor MI, US
James A. Shayman - Ann Arbor MI, US
Assignee:
The Regents of The University of Michigan - Ann Arbor MI
International Classification:
A61K 31/4025, C07D 207/09, A61K 31/40, A61P 25/16, A61P 25/00, A61K 48/00, A61P 7/06, A61P 35/00, A61P 13/12, A61P 9/10, A61P 31/00, A61K 38/43, C07D 405/10, A61P 3/10
US Classification:
424 941, 548526, 514422, 548569, 514428, 548568, 514 44 R
Abstract:
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
US Patent:
6030995, Feb 29, 2000
Filed:
Oct 29, 1998
Appl. No.:
9/182161
Inventors:
James A. Shayman - Ann Arbor MI
Norman S. Radin - Ann Arbor MI
Norman S. Radin - Ann Arbor MI
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 3140
US Classification:
514428
Abstract:
Novel amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
US Patent:
6051598, Apr 18, 2000
Filed:
Jun 26, 1997
Appl. No.:
8/883218
Inventors:
James A. Shayman - Ann Arbor MI
Norman S. Radin - Ann Arbor MI
Norman S. Radin - Ann Arbor MI
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 3140
US Classification:
514428
Abstract:
Novel amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
US Patent:
6916802, Jul 12, 2005
Filed:
May 5, 2004
Appl. No.:
10/839497
Inventors:
James A. Shayman - Ann Arbor MI, US
David J. Harris - Lexington MA, US
Craig Siegel - Woburn MA, US
Carol A. Nelson - Westford MA, US
Diane P. Copeland - North Billerica MA, US
David J. Harris - Lexington MA, US
Craig Siegel - Woburn MA, US
Carol A. Nelson - Westford MA, US
Diane P. Copeland - North Billerica MA, US
Assignee:
Genzyme Corporation - Cambridge MA
The Regents of the University of Michigan - Ann Arbor MI
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K031/40, A61K031/445, A61K031/5375, C07D207/16, C07D211/34
US Classification:
51421001, 5142338, 5142378, 514315, 514321, 514331, 514422, 514428, 544148, 544168, 546197, 546233, 548528, 548568, 548950
Abstract:
The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Amino Ceramide - Like Compounds And Therapeutic Methods Of Use
Amino Ceramide - Like Compounds And Therapeutic Methods Of Use
US Patent:
2002019, Dec 26, 2002
Filed:
Apr 29, 2002
Appl. No.:
10/134314
Inventors:
James Shayman - Ann Arbor MI, US
Norman Radin - Cupertino CA, US
Norman Radin - Cupertino CA, US
International Classification:
A61K031/445, A61K031/401, A61K031/16
US Classification:
514/354000, 514/464000, 514/625000, 546/314000, 554/051000, 549/440000, 514/423000, 548/530000
Abstract:
Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
US Patent:
2009031, Dec 17, 2009
Filed:
Apr 30, 2009
Appl. No.:
12/387273
Inventors:
James A. Shayman - Ann Arbor MI, US
David J. Harris - Lexington MA, US
Craig Siegel - Woburn MA, US
Carol A. Nelson - Westford MA, US
Diane P. Copeland - North Billerica MA, US
David J. Harris - Lexington MA, US
Craig Siegel - Woburn MA, US
Carol A. Nelson - Westford MA, US
Diane P. Copeland - North Billerica MA, US
International Classification:
A61K 31/40, C07D 207/04, A61P 43/00
US Classification:
514428, 548571
Abstract:
The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
US Patent:
5952370, Sep 14, 1999
Filed:
Jun 26, 1997
Appl. No.:
8/882772
Inventors:
James A. Shayman - Ann Arbor MI
Norman S. Radin - Ann Arbor MI
Norman S. Radin - Ann Arbor MI
Assignee:
The Regents of University of Michigan - Ann Arbor MI
International Classification:
A61K 3140
US Classification:
514428
Abstract:
Novel amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
Amino Ceramide-Like Compounds And Therapeutic Methods Of Use
US Patent:
6890949, May 10, 2005
Filed:
Jul 7, 2000
Appl. No.:
10/030963
Inventors:
James A. Shayman - Ann Arbor MI, US
Norman S. Radin - Menlo Park CA, US
Norman S. Radin - Menlo Park CA, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K031/4025
US Classification:
514422, 514428, 548526, 548568
Abstract:
Novel amino ceramide-like compounds (1) are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.